title: [Expression of excision repair cross-complementation gene in drug-resistant process of carboplatin administration in tongue squamous cell cancer (Tca8113)].
abstract: OBJECTIVE
  To investigate the correlations between the resistant degree of Tca8113 agaist carboplatin and the expression of excision repair cross-complementation 1 (ERCC-1).
  
  
  METHODS
  Tca8113 cells were exposed in the carboplatin solutions of gradually increasing concentration. Cancer cells were divided into six experimental groups and a control group. In the course of culture, the half inhibitory concentration (IC(50)) of each groups were detected by methyl thiazolyl tetrazolium (MTT). The expressions of ERCC-1 at mRNA and protein level were detected by reverse transcription polymerase chain reaction (RT-PCR) and Western blotting.
  
  
  RESULTS
  With the increase of drug resistance, the expression of ERCC-1 increased gradually at mRNA level (control group: 0.84 ± 0.06, group 1: 0.96 ± 0.06, group 2: 1.07 ± 0.11, group 3: 1.13 ± 0.09, group 4: 1.19 ± 0.08, group 5: 1.29 ± 0.07, group 6: 1.47 ± 0.08), values between neighboring or interval groups have significant differences (P < 0.05); the expression of ERCC-1 increased gradually at protein level (control group: 0.69 ± 0.05, group 1: 0.86 ± 0.04, group 2: 1.01 ± 0.04, group 3: 1.24 ± 0.09, group 4: 1.44 ± 0.14, group 5: 1.56 ± 0.19, group 6: 1.88 ± 0.22), values between neighboring or interval groups have significant differences (P < 0.05). The gradually increasing RT-PCR gray values were related to the gradually increasing IC(50) in all groups (r = 0.91, P < 0.01), and the gradually increasing western blotting gray values were also related to the gradually increasing IC(50) in all groups (r = 0.88, P < 0.01).
  
  
  CONCLUSIONS
  The high expression of ERCC-1 may become an indicator of Tca8113 resisting carboplatin. This might provide a potential target to reverse tongue squamous cell cancer (Tca8113) that has resistance to carboplatin.
authors: Department of Oral and Maxillofacial Surgery, Chongqing Medical University, Chongqing, China.
authors: Xian
authors: X
authors: Li
authors: Yong
authors: Y
authors: Li
authors: Li-hua
authors: LH
authors: Qiu
authors: Xi
authors: X
authors: Tong
authors: Qi-ming
authors: QM
authors: Wang
authors: Ting
authors: T
authors: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D016190:Carboplatin / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D020128:Inhibitory Concentration 50; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014062:Tongue Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D016190:Carboplatin; C071447:ERCC1 protein, human; D004720:Endonucleases